Compare ICON & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICON | ARTL |
|---|---|---|
| Founded | 2023 | 2011 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 3.4M |
| IPO Year | 2024 | N/A |
| Metric | ICON | ARTL |
|---|---|---|
| Price | $0.71 | $1.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $4.50 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 1.8M | 1.2M |
| Earning Date | 04-02-2026 | 11-12-2025 |
| Dividend Yield | ★ 1317.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,449,000.00 | N/A |
| Revenue This Year | $94.05 | N/A |
| Revenue Next Year | $18.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 96.44 | N/A |
| 52 Week Low | $0.69 | $1.52 |
| 52 Week High | $106.60 | $28.60 |
| Indicator | ICON | ARTL |
|---|---|---|
| Relative Strength Index (RSI) | 26.18 | 42.42 |
| Support Level | $0.72 | $1.69 |
| Resistance Level | $0.83 | $1.94 |
| Average True Range (ATR) | 0.08 | 0.20 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 8.37 | 76.76 |
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.